|Day Low/High||3.10 / 3.14|
|52 Wk Low/High||2.55 / 5.39|
Company Initiates CEO Succession Plan
Aastrom Biosciences' CEO Discusses Q2 2012 Results - Earnings Call Transcript
A $40 million financing pays for Aastrom's phase III study of a cellular therapy in patients with severely blocked leg arteries.
Biotech columnist Adam Feuerstein responds to biotech stock questions posed by his Twitter followers.
Raising $30 million this quarter will full fund Aastrom's phase III study of its cellular therapy for patients with blocked leg arteries.
Final mid-stage data from Aastrom's personalized cellular therapy were presented today.
Here's a list of November's potentially stock-moving biotech events.
Here's a list of September's potentially stock-moving biotech events.
These high-risk, high-reward biotech stocks have the potential for big gains if they can overcome significant challenges.
TheStreet's biotech columnist Adam Feuerstein is holding a live, interactive discussion about biotech stock investing.
Biotech columnist Adam Feuerstein answers readers' questions and concerns about health care and drug-related stocks.
TheStreet presents a rundown of the winners in the small-cap space during the day's trading.
Conference Call Scheduled Today at 4:30 PM EST
Special Meeting of Shareholders Scheduled for March 21 to Consider Share Authorizations
TheStreet's Adam Feuerstein blogs a conference in New York for smaller biotechs.
Adam Feuerstein's take on the biotech sector's hits and misses during the week ended Dec. 10, 2010.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.